ALC

Business Context and Reporting Period

Company: Alcon, Inc. (Swiss corporation, majority-owned subsidiary of Nestlé S.A.)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Three months ended March 31, 2005 (Q1 2005)
Filing Date: April 22, 2005

Alcon operates globally through two segments: Alcon United States and Alcon International. The company markets products in three categories: pharmaceuticals, surgical equipment/devices, and consumer eye care.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Sales increased 11.1% year-over-year. Organic growth (constant currency) was 8.5%, driven by volume increases. Foreign exchange contributed 2.6% to the reported growth.
• Profitability: Net earnings rose 30.6% to $249.5 million. Operating income increased 18.1% to $326.8 million.
• Margin Expansion: Gross margin improved to 73.0% from 69.9%, attributed to favorable product mix, lower manufacturing costs, and currency impacts.
• Segment Performance:
  • United States: Sales up 7.5%; Operating income up 7.1%.
  • International: Sales up 14.7% (9.6% constant currency); Operating income up 26.5%.
• Product Drivers:
  • Pharmaceuticals: Sales up 14.0%. Growth led by Vigamox (anti-infective), Travatan (glaucoma), and Patanol (allergy). Decline in branded fluoroquinolones (Ciloxan) due to patent expiration was offset by generic sales via Falcon subsidiary.
  • Surgical: Sales up 10.0%. Driven by AcrySof Natural and ReSTOR intraocular lenses and the Infiniti vision system.
  • Consumer Eye Care: Sales up 6.8%. Artificial tears (Systane) grew 26.7%.
• Tax Rate: Effective tax rate decreased to 24.0% from 31.0%, partly due to a one-time tax benefit in the prior year and a strategic shift to fund more R&D in the U.S.

Guidance, Outlook, and Risks

• Dividend: Management expects to declare a dividend of approximately $1.00 per share (CHF 1.18), totaling an estimated $305 million, subject to shareholder approval on May 3, 2005.
• Future Tax Outlook: The company expects the effective tax rate to decrease by 3-4% in 2005 and further decline by 2-3% annually in 2006 and 2007 due to increased U.S. R&D deductions.
• Product Launches: AcrySof ReSTOR intraocular lenses received FDA approval in late March 2005; commercial shipments in the U.S. expected to begin in May 2005.
• Legal Proceedings: A patent infringement lawsuit filed by Advanced Medical Optics, Inc. regarding the Infiniti and Legacy surgical systems is scheduled for trial on April 25, 2005. Alcon intends to vigorously defend the claims.
• Accounting Changes: The company plans to adopt SFAS No. 123 (revised 2004) regarding share-based payment effective January 1, 2006. Proforma net earnings for Q1 2005 under this standard would have been $220.9 million.
• Market Risks: Significant exposure to foreign currency fluctuations and interest rate changes on short-term floating-rate debt. Credit risk is managed through diversification and hedging.

Investor Verification Checklist

• Patent Expiration Impact: Verify the continued decline in branded fluoroquinolone sales (Ciloxan) and the market share capture by the Falcon generic subsidiary.
• ReSTOR Lens Adoption: Monitor the commercial uptake of the newly FDA-approved AcrySof ReSTOR lens starting May 2005.
• Legal Outcome: Track the April 25, 2005 trial date for the Advanced Medical Optics patent infringement case.
• Dividend Approval: Confirm shareholder approval of the proposed $305 million dividend at the May 3, 2005 meeting.
• Share Repurchases: Note the company spent $87.6 million on treasury shares in Q1 2005; verify remaining authorization limits for future buybacks.
• Tax Rate Sustainability: Assess the long-term sustainability of the projected lower effective tax rates based on U.S. R&D funding shifts.